Back to Search
Start Over
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
- Source :
- Journal for Immunotherapy of Cancer, Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
- Publication Year :
- 2021
- Publisher :
- BMJ Publishing Group, 2021.
-
Abstract
- Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer therapy, such as chemotherapy, radiotherapy, or targeted therapy, is also expanding. However, immune-related adverse events (irAEs) can be serious in up to a third of patients. Critical questions remain surrounding the characteristics and outcomes of irAEs, and how they may affect the overall risk–benefit relationship for combination therapies. This article proposes a framework for irAE classification and reporting, and identifies limitations in the capture and sharing of data on irAEs from current clinical trial and real-world data. We outline key gaps and suggestions for clinicians, clinical investigators, drug sponsors, patients, and other stakeholders to make these critical data more available to researchers for pooled analysis, to advance contemporary understanding of irAEs, and ultimately improve the efficacy of ICIs.
- Subjects :
- 0301 basic medicine
Cancer Research
medicine.medical_specialty
immune tolerance
Drug-Related Side Effects and Adverse Reactions
Immune checkpoint inhibitors
medicine.medical_treatment
Immunology
Targeted therapy
03 medical and health sciences
0302 clinical medicine
Immune system
Position Article and Guidelines
Neoplasms
Biomarkers, Tumor
Immunology and Allergy
Medicine
Humans
Intensive care medicine
Adverse effect
Immune Checkpoint Inhibitors
RC254-282
Pharmacology
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cancer
medicine.disease
Call to action
Clinical trial
Radiation therapy
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
tumor biomarkers
translational medical research
Molecular Medicine
immunotherapy
business
guidelines as topic
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 9
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Journal for Immunotherapy of Cancer
- Accession number :
- edsair.doi.dedup.....548612cdcb271f069d4e64f2c99e383d